Revised Ph. Eur. Monographs on Excipients due to ICH Q3D
Recommendation

16-18 June 2026
Management, Supply and Quality Assurance of Clinical Trials
Several revised Ph. Eur. Monographs on excipients commonly used in semi-solid formulations (e.g. oils, fats, waxes, emulsifiers) have been proposed in Pharmeuropa 30.2. Deadline for comments is June 30, 2018.
In line with the Ph. Eur. implementation strategy for the ICH Q3D guideline on elemental impurities, the test on Nickel is proposed for deletion as the relevant elemental impurities are considered to originate from the production process. A change to this effect has been introduced in the Production section of the general Ph. Eur. monograph “Substances for pharmaceutical use” (with Ph. Eur. supplement 9.3), as only the manufacturer of a substance for pharmaceutical use knows which elemental impurities may be potentially introduced as catalysts and reagents, and whose levels would therefore need to be controlled.
This affects the following Ph. Eur. Monographs:
- Hard fat
- Hard fat with additives
- Arachis oil, hydrogenated
- Castor oil, hydrogenated
- Cottonseed oil, hydrogenated
- Glycerol dibehenate
- Glycerol distearate
- Glycerol monostearate 40-55
- Macrogol 15 hydroxystearate
- Macrogol 30 dipolyhydroxystearate
- Palmitic acid
- Stearic acid
- Soya-bean oil, hydrogenated
- Squalane
- Triglycerides, medium-chain (additional removal of the tests for Chromium, Copper, Lead, Tin)
Furthermore, a draft for a new monograph on Cocoa butter has been published for comment in the same issue of Pharmeuropa.
For more information plese see Pharmeuropa Online.
Related GMP News
18.05.2026EMA updates Q&A on Reduced Testing of Incoming Starting Materials
18.05.2026China: NMPA publishes Draft Guidance on Inspection of Data Integrity in QC Laboratories
18.05.2026FDA Warning Letter to EU OTC Manufacturer
13.05.2026BP Publishes Key Insights on Chromatography and SST
06.05.2026Laboratory Controls in Focus in FDA Warning Letter to U.S. OTC Manufacturer
06.05.2026WHO Working Document on Bioequivalence open for Public Consultation


